CHM
CHIMERIC THERAPEUTICS LIMITED
$0.0050
▲ +25.00%
Market cap
—
Turnover
$5,733
Last price
$0.0050
Day change
+25.00%
Announcements
11
Range, past year
Open 0.003 · Low 0.001 · Now 0.005 · High 0.200
Open CHM in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CHM momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-29.
Momentum quality
38/100
Wyckoff phase
Downtrend28d
Trend stage
Neutral
1 Day
+25.0%
1 Week
-16.7%
1 Month
-54.5%
RSI
30
Avg daily range
34.0%
CHIMERIC THERAPEUTICS LIMITED scores 38 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Downtrend, where it has been for 28 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.90 — highly linear uptrend
- Volume 1.6× 60-day avg
Points to watch
- 60d drawdown -92.9%
- High volatility (ATR 34.0%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsCHM announcements
Recent price-sensitive releases.
- 2026-08-31 Appendix 4E and Preliminary Final Report Preliminary Final Report
- 2026-08-19 CHM ceases enrolment in Phase 1 trial and Company update Notification of Results/Reporting Date | Trading Halt Lifted | Progress Report
- 2026-08-17 Trading Halt Trading Halt
- 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Web Cast | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-29 Chimeric receives $1.62M advance on FY26 R&D tax incentive Progress Report | Debt Facility
- 2026-07-16 CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- 2026-07-01 Appointment of Financial Adviser for Strategic Review
More Health Care stocks
Most traded in the same sector.